UBS Group
PMVP icon

UBS Group’s PMV Pharmaceuticals PMVP Stock Holding History

UBS Group’s Portfolio PMVP Stock Details PMVP Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q3 		$603 Hold
361
– – ﹤0.01% 10551
2026
Q2 		$484 Hold
361
– – ﹤0.01% 9833
2026
Q1 		$448 Sell
361
-737
-67% -$937 ﹤0.01% 9891
2025
Q4 		$1.37K Sell
1,098
-453
-29% -$607 ﹤0.01% 9606
2025
Q3 		$2.17K Sell
1,551
-120,759
-99% -$167K ﹤0.01% 9210
2025
Q2 		$130K Sell
122,310
-29,973
-20% -$29.4K ﹤0.01% 7023
2025
Q1 		$166K Sell
152,283
-123,181
-45% -$167K ﹤0.01% 6667
2024
Q4 		$416K Buy
275,464
+96,598
+54% +$153K ﹤0.01% 5969
2024
Q3 		$267K Buy
178,866
+93,963
+111% +$145K ﹤0.01% 5661
2024
Q2 		$138K Sell
84,903
-48,721
-36% -$87.9K ﹤0.01% 5941
2024
Q1 		$227K Buy
133,624
+5,756
+5% +$10.8K ﹤0.01% 5771
2023
Q4 		$396K Sell
127,868
-15,813
-11% -$41.8K ﹤0.01% 5289
2023
Q3 		$882K Buy
143,681
+45,962
+47% +$316K ﹤0.01% 4187
2023
Q2 		$612K Buy
97,719
+8,075
+9% +$42.3K ﹤0.01% 4660
2023
Q1 		$428K Sell
89,644
-194,744
-68% -$1.37M ﹤0.01% 4811
2022
Q4 		$2.47M Buy
284,388
+164,543
+137% +$1.75M ﹤0.01% 3182
2022
Q3 		$1.43M Sell
119,845
-230,465
-66% -$3.33M ﹤0.01% 3453
2022
Q2 		$4.99M Buy
350,310
+161,299
+85% +$2.35M ﹤0.01% 2380
2022
Q1 		$3.94M Buy
189,011
+60,104
+47% +$1.06M ﹤0.01% 2777
2021
Q4 		$2.98M Buy
128,907
+32,869
+34% +$794K ﹤0.01% 3362
2021
Q3 		$2.86M Buy
96,038
+94,956
+8,776% +$3.03M ﹤0.01% 3249
2021
Q2 		$37K Sell
1,082
-11,857
-92% -$396K ﹤0.01% 6723
2021
Q1 		$426K Buy
12,939
+10,413
+412% +$410K ﹤0.01% 4995
2020
Q4 		$155K Buy
2,526
+1,955
+342% +$76.7K ﹤0.01% 5403
2020
Q3 		$20K Buy
+571
New +$21K ﹤0.01% 6312

Other funds holding PMVP

BCM
BML Capital Management Zionsville, Indiana $188M AUM 88.51% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.76T AUM
Acadian Asset Management
Acadian Asset Management Boston, Massachusetts $85.7B AUM 51.02% 1-Year Est. Return
Affinity Asset Advisors
Affinity Asset Advisors New York $2.46B AUM 196.28% 1-Year Est. Return
BlackRock
BlackRock New York $6.79T AUM 37.06% 1-Year Est. Return
BIT Capital
BIT Capital Berlin, Germany $2.89B AUM 111.72% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.92T AUM 36.1% 1-Year Est. Return
Aldebaran Capital
Aldebaran Capital Carmel, Indiana $139M AUM 35.88% 1-Year Est. Return
Walleye Capital
Walleye Capital New York $109B AUM 29.28% 1-Year Est. Return
Assenagon Asset Management
Assenagon Asset Management Senningerberg, Luxembourg $103B AUM 40.17% 1-Year Est. Return

UBS Group's PMVP Position: Q3 2026 in Review

UBS Group held its PMV Pharmaceuticals (PMVP) position steady in Q3 2026 at 361 shares worth $603. The position accounts for ﹤0.01% of the portfolio, ranked #10551.

UBS Group first reported a position in PMVP in Q3 2020 and has held it in 25 quarters since. The position peaked at $4.99M in Q2 2022. 36 funds tracked by Wall St. Rank hold PMVP as of Q3 2026.

  • UBS Group held 361 shares of PMV Pharmaceuticals worth $603 as of Q3 2026.
  • UBS Group left its PMV Pharmaceuticals share count unchanged in Q3 2026.
  • PMV Pharmaceuticals made up ﹤0.01% of UBS Group's portfolio in Q3 2026, its #10551 holding.
  • UBS Group first reported a position in PMV Pharmaceuticals in Q3 2020 and has held it in 25 quarters since.
  • UBS Group's PMV Pharmaceuticals position peaked at $4.99M in Q2 2022.
  • 36 funds tracked by Wall St. Rank held PMV Pharmaceuticals as of Q3 2026.

Based on UBS Group's 13F filing for Q3 2026, filed 10 Nov 2026.